Has anyone dealt with rybelsus real-world vs clinical trial efficacy?

BethLabQueen said:

One practical note: write down what you did and when, before you need it.

That is correct as far as it goes, and here is where it stops going. Yes, and the corollary is less popular: if the reasoning holds, it also holds where it produces an answer we do not like.

Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

BethLabQueen said:

One practical note: write down what you did and when, before you need it.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Sending this to two other people who asked me the same thing last week.

Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

traveltech_sara said:

If two explanations both fit, the useful question is which one predicts something the other does not.

This is my experience too, for whatever a second data point is worth.

traveltech_sara said:

If two explanations both fit, the useful question is which one predicts something the other does not.

Adding the part of the answer the thread has not reached. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.